NewLimit's age-reprogramming sprint: 5000+ payloads tested, 314X manufacturing scale-up
jacobkimmel · x · 2026-10-22
NewLimit published its 2026 Summer update, claiming more drug development milestones this quarter than in the rest of its history.
Key numbers:
- >2X stronger regenerative rescue in old hepatocytes
- +8 payloads restore endothelial function, +5 in hepatocytes
- 314X scale-up in therapeutic manufacturing with 13X quality improvement
- >5000 payloads tested for cell-age effects (all-time high)
- 2.5X better endothelial cell age prediction; 5X data-efficiency gain via transfer learning
The team also hired Hank Mansbach (ex-89bio CMO) as Head of Clinical Development, ran its first large-animal studies, and started engaging with regulators.
More from AGI Musings
- Paper: 288M job postings reveal where AI raises the value of work it can't do — soumitrashukla9 · 2026-10-22
- Aaron Levie: autonomous domain-specific agents are AI's emerging form factor, a leap past the LLM-wrapper era — _AustinCalvert_ · 2026-10-22
- Widening AI Ceiling-Floor Gap Means More 'Out of Distribution' Events — curious_vii · 2026-10-22
- Google researchers test an AI job-impact site: 'bluer the collar, the later the deprecation' — giffmana · 2026-10-22
- Every major AI company now ships a personal agent except Google, argues signulll — signulll · 2026-10-22
- Instinct CEO: A Smarter Agent Is a Better Persuader, So It Must Never Steer You — rohanpaul_ai · 2026-10-22